

ACTIVITIES REPORT FOR THE QUARTER ENDED 31 DECEMBER 2024

HIGHLIGHTS

- MoU signed with Miami-based Managed Service Organisation (MSO) Provider Network Solutions LLC (PNS) for Singular Health's 3Dicom software
- The MOU provides a definitive pathway towards an initial commercial pilot, a subsequent full-scale rollout throughout the PNS network, and a planned National rollout to PNS' wider network.
- Successful demonstration of Phase 1 of the MOU subsequent to end of quarter including the application of a 3rd party artificial intelligence model to generate valuable meta-data for further analysis by PNS.
- Successful placement of A\$3.7m at \$0.09 per share, including A\$500,000 cornerstone investment by PNS and follow on investment from Marin and Sons.
- Placement funds will be used towards further development of 3Dicom software, MOU implementation and advancement towards a commercial pilot program along with working capital
- Appointment of Dr. Ronny Low, a highly regarded and well-credentialed Australian radiologist, as a Technical Advisor to support the implementation of the US Pilot Project with PNS.
- Successful completion of the research collaboration with Edith Cowan University (ECU) and Arthritis and Osteoporosis WA Foundation (AOWA).
- Strong cash position of \$4.6m and debt free as at 31 December 2024

28 January 2025 - Medical technology company Singular Health Group Limited (ASX: SHG) ("Singular Health" or the "Company") is pleased to provide shareholders with an operational and financial update for the transformational quarter ending 31st December 2024 ("Quarter").

Memorandum of Understanding signed with Provider Network Solutions (PNS)

As announced in the ASX Announcement "*Capital Raising and MOU with PNS for Commercial Pilot*", 20th November 2024, Singular entered a Memorandum of Understanding (MOU) with Provider Network Solutions (PNS) to collaborate on a technical proof-of-concept and commercial pilot within the PNS Network.

PNS is a Miami-based Managed Service Organisation (MSO) with operations in Florida, Texas, and Puerto Rico, managing the provision of healthcare for more than 3.7 million Member Plans.

The MOU followed on from a lengthy period of co-design with PNS and is structured to demonstrate the feasibility of Singular Health's 3Dicom solution in solving multiple, highly valuable workflows within PNS's network, to target the reduction in duplicate imaging and improving access to imaging across disparate PACs systems along with applying analysis to historical and recent images.

The MOU is structured in four phases:

- Phase 1 - Technical Proof of Concept,
- Phase 2 - Commercial Planning and Budgeting of Pilot Program,
- Phase 3 - Implementation of Pilot Program, and
- Phase 4 - Upon Success of Pilot Program – the Planning of National Rollout

The technical proof-of-concept demonstrates Singular Health's proprietary, patent-pending Medical File Transfer Protocol (MFTP), which aggregates siloed medical imaging and enables AI models to analyse data in transit. This allows for additional review and quantitative analysis of existing images without increasing the workload of radiologists.

Subsequent to the Quarter, the Company announced the successful demonstration of the Technical Proof of Concept during which multiple demonstrative healthcare facilities were set up in various geographical locations and configured similar to those in the actual PNS network (refer ASX announcement 17 January 2025).

Singular Health then demonstrated not only the rapid search and retrieval of medical images from each facility to a centralised online portal, but also the application of a 3rd party artificial intelligence model to the data to generate valuable meta-data for further analysis by PNS.

SHG and PNS now moving into implementing and satisfying Phase 2 of the Memorandum of Understanding, being the commercial planning and budgeting of a pilot program.

The pilot program is being co-designed with PNS to allow the implementation of the 3Dicom solution into a limited number of PNS affiliated facilities in either Florida, Texas, or Puerto Rico for a period of up to 6 months to quantify the reduction in duplicate imaging, time saved in CD-less transfers, and improvements to patient care.

Subject to the success of the pilot program, PNS and Singular will then collaborate with a plan to onboard additional MSOs and rollout the system to PNS's entire network of affiliated healthcare facilities covering their more than 3.7 million members.

Successful Equity Raising of AUD\$3.7 million with \$500,000 cornerstone from PNS

Concurrent with the signing of the MOU with PNS, the Company undertook a \$3.7 million equity raise at \$0.09 led by Perth-based Wallabi Group. The raising was well supported with PNS subscribing for AUD\$500,000, existing shareholder Marin & Sons subscribing for AUD\$200,000 and the remaining \$3,000,000 allocated to institutional, wholesale and sophisticated investors.

During the quarter 4.2m options were exercised at 10c each contributing to an increase in the Company's cash reserves of ~\$420,000.

Appointment of Dr Ronny Low, renowned radiologist, as Technical Advisor

Dr Ronny Low, a well-regarded practicing radiologist with over 20 years of clinical experience, has joined the company in an advisory capacity as a subject matter expert (Radiology IT Architect and Radiologist) under the terms of the MOU with PNS.

A highly accomplished radiologist, Dr Low has held numerous positions within RANZCR and currently serves as a member of the Clinical Radiology Education and Training Committee and in January commences a term on their Clinical Radiology Curriculum Advisory Committee.

Dr Low's current Appointments include:

- Network Training Director, WA Radiology Training Program
- Consultant Radiologist – Fiona Stanley Hospital, Fremantle Hospital, Rockingham General Hospital, Envision Medical Imaging
- Chairperson CT Reference Group, RANZCR
- Member of the Therapeutic Goods Administration Advisory Committee on the Safety of Gadolinium

Over and above his clinical work, his experience spans business development, improvement, and innovation. Dr Low was instrumental in growing Envision Medical Imaging in Perth prior to it being sold to a large private equity owned group in 2022.

Further detail is provided in the ASX announcement dated 23 December 2024, including in respect of incentive options to be issued to Dr Low, subject to shareholder approval.

Completion of the Joint Research Project Conducted with ECU and AOWA

The Company is pleased to announce the successful completion of the Bone and Joint Health Project, a collaborative research project conducted in collaboration with Edith Cowan University (ECU) and the Arthritis and Osteoporosis WA Foundation (AOWA). The project aims to raise awareness of the importance of joint and bone health in adolescence to prevent conditions such as osteoporosis, osteopenia and arthritis. This initiative reflects the Company's commitment to advancing innovative solutions in the medical education space while fostering partnerships with leading academic and not-for-profit organisations.

Over the course of the 2-year project, the team has co-designed, developed, implemented, and validated across 400 participants, curriculum-aligned and digitally immersive educational and learning resources tailored to secondary school students, particularly Y7-10 adolescents.

The project resulted in the development of a resource package comprising a serious game, a resource book for teachers, and a set of animations on bone and joint health concepts.

The collaboration has reinforced Singular Health's capability to translate research into practical applications while contributing to strengthening the company's financial position.

Additional information about the project and the resources can be accessed at <https://skeletalcentral.com>.

Activities Subsequent to Period End

The Company continues its efforts to consolidate and expand its reach in various international markets in the medical education sector, as demonstrated by two recent enterprise sales. The first one is the renewal of the yearly license agreement with Majmaah University (Saudi Arabia), underscoring the institution's continued trust in our 3Dicom solution.

The second involves strategic initiatives to distribute our licenses to medical students across multiple universities in India, supporting the development of future healthcare professionals in one of the largest educational markets.

These milestones reinforce our commitment to delivering value to the academic and medical communities with our existing 3Dicom solutions.

Financial Review

As at 31 December 2024, the Company held cash of \$4.6m an increase of \$2.94m from prior quarter. Net cash used from operating activities was \$940k. The Company had cash inflows of \$3.2m from a capital raising, \$436k from options exercised and \$355k from R&D Grant. Refer to the attached cash flow report for further information.

Corporate Activities

In accordance with Listing Rule 4.7C.3, the Company advises that payments to related parties of the entity and their associates during the Quarter amounted to \$104,000.

Amounts included in 6.1 attached 4C relates to amounts paid to related parties of the entity and their associates.

Further funds are anticipated to be received in the current quarter including PNS's \$500k participation in the November placement (subject to shareholder approval) and Marin & Sons' \$773k participation in a previous capital raising.

A notice of meeting containing further detail will be dispatched to shareholders shortly in respect of a shareholder meeting to approve various items including PNS's capital raising participation, the approval of the issue of the incentive options to Dr Low, in addition to a long-term incentive option package to the Company's Managing Director and non-executive director options.

Authorised for release by the Board of Directors.

Ends

For further information contact

Denning Chong
Managing Director & CEO
denning@singular.health
1300 167 795

Paul Berson
Investor Relations
paul@corporatestorytime.com
+61 421 647 445

About Singular Health

Singular Health is a Western Australian, ASX-listed (ASX: SHG) medical technology company on a mission to create a seamless and integrated healthcare ecosystem where the full value of medical imaging records is unlocked, enabling universal access and promoting interoperability to maximise patient outcomes.

Singular Health's 3Dicom software solutions empower patients and practitioners to better visualise, communicate, and understand medical imaging data. 3Dicom MD® is cleared for diagnostic use in the United States.

To learn more, visit <https://singular.health> and <https://investors.singular.health/>

For personal use only

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Singular Health Group Limited

ABN

58 639 242 765

Quarter ended ("current quarter")

31 December 2024

	Current quarter \$A'000	Year to date (6 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	40	96
1.2 Payments for		
(a) research and development	(215)	(353)
(b) product manufacturing and operating costs	(2)	(5)
(c) advertising and marketing	(70)	(125)
(d) leased assets	(4)	(12)
(e) staff costs	(365)	(748)
(f) administration and corporate costs	(263)	(465)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	16	29
1.5 Interest and other costs of finance paid	(21)	(24)
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	355	355
1.8 Other	-	-
1.9 Net cash from / (used in) operating activities	(529)	(1,252)
2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	-	-
(d) investments	-	-
(e) intellectual property	-	-
(f) other non-current assets	-	-

For personal use only

	Current quarter \$A'000	Year to date (6 months) \$A'000
2.2		
Proceeds from disposal of:		
(a) entities	41	41
(b) businesses	-	-
(c) property, plant and equipment	-	60
(d) investments	-	-
(e) intellectual property	-	-
(f) other non-current assets	-	-
2.3	-	-
Cash flows from loans to other entities	-	-
2.4	-	-
Dividends received (see note 3)	-	-
2.5	-	-
Other	-	-
2.6	41	101
Net cash from / (used in) investing activities		
3.		
Cash flows from financing activities		
3.1		
Proceeds from issues/unissued of equity securities (excluding convertible debt securities)	3,209	4,209
3.2	-	-
Proceeds from issue of convertible notes	-	-
3.3	436	436
Proceeds from exercise of share options	436	436
3.4	(21)	(89)
Transaction costs related to issues of equity securities or convertible debt securities	(21)	(89)
3.5	-	-
Proceeds from borrowings	-	-
3.6	(191)	(205)
Repayment of borrowings	(191)	(205)
3.7	-	-
Transaction costs related to loans and borrowings	-	-
3.8	-	-
Dividends paid	-	-
3.9	(6)	(26)
Other – lease payments	(6)	(26)
3.10	3,427	4,325
Net cash from / (used in) financing activities		
4.		
Net increase / (decrease) in cash and cash equivalents for the period		
4.1		
Cash and cash equivalents at beginning of period	1,688	1,455
4.2	(527)	(1,252)
Net cash from / (used in) operating activities (item 1.9 above)	(527)	(1,252)
4.3	41	101
Net cash from / (used in) investing activities (item 2.6 above)	41	101

For personal use only

Quarterly cash flow report for entities subject to Listing Rule 4.7B

		Current quarter \$A'000	Year to date (6 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	3,427	4,325
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	Cash and cash equivalents at end of period	4,629	4,629

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	529	88
5.2	Call deposits	4,100	1,600
5.3	Bank overdrafts	-	-
5.4	Other (Joint Venture Cash Entitlement)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	4,629	1,688

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	104
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
6.3	Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2	-
	- Salary to Managing Director (\$70k) and aggregate amount paid to Non-Executive Director fees (\$31k) and payment of (\$3k) to director related entity for legal services.	

For personal use only

7. Financing facilities	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
<i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>		
7.1 Loan facilities	-	-
7.2 Credit standby arrangements	-	-
7.3 Other (please specify)	-	-
7.4 Total financing facilities	-	-
7.5 Unused financing facilities available at quarter end		-
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.	-	

8. Estimated cash available for future operating activities	\$A'000
8.1 Net cash from / (used in) operating activities (item 1.9)	(527)
8.2 Cash and cash equivalents at quarter end (item 4.6)	4,629
8.3 Unused finance facilities available at quarter end (item 7.5)	-
8.4 Total available funding (item 8.4 + item 8.5)	4,629
8.5 Estimated quarters of funding available (item 8.6 divided by item 8.3)	8.78
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
Answer: N/A	
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
Answer: N/A	
8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
Answer: N/A	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

28 January 2025

Date:

The Board of Directors

Authorised by:
 (Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.